KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.

Qingling Zhang, Nanshan Zhong, Sahajal Dhooria, Xiuhua Fu, Haohui Fang, Jie Lin, Shuyang Zhu, Elizabeth Laws, Yi Wang, Vivian Li, Chih-Chi Hu, Jennifer Maloney, Raolat M Abdulai, Lacey B Robinson

Clin Exp Allergy 55(8) 691-700

PMID39988927
PMCIDPMC12325141
DOI10.1111/cea.70005
发表日期2025-02-24
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Asthma prevalence is increasing in the Asia-Pacific region. China and India account for > 35% of the world's population and are often underrepresented in clinical studies. This phase 3 study (NCT03782532) evaluated efficacy and safety of dupilumab, a monoclonal antibody blocking interleukin-4/13 signalling, in patients with persistent asthma from China and India. METHODS: Patients (≥ 12 years) were randomised 1:1 to dupilumab 200 mg or matched placebo every 2 weeks for 24 weeks (primary analysis population: blood eosinophils ≥ 150 cells/μL or fractional exhaled nitric oxide ≥ 25 parts per billion without maintenance oral corticosteroid [OCS]; OCS maintenance population: 300 mg OCS). PRIMARY ENDPOINT: change from baseline to week 12 in forced expiratory volume in 1 s (FEV1). Secondary endpoints: change from baseline to week 24 in 5-item Asthma Control Questionnaire (ACQ-5/7) scores, annualised severe exacerbation rate, and safety. RESULTS: In the primary analysis population (n = 414), change in FEV1 by week 12 was significantly greater for dupilumab versus placebo (least squares mean difference: 0.31 L [95% CI: 0.23-0.39]; p < 0.0001). At week 24, greater reductions in ACQ-5 score were seen for dupilumab versus placebo (least squares mean difference: -0.20 [95% CI: -0.35 to -0.05]; p = 0.0097). Dupilumab reduced severe exacerbation risk by 62% versus placebo during the treatment period (relative risk: 0.38 [95% CI: 0.21-0.70]; nominal p = 0.002). Safety was similar between treatment arms; injection-site reactions were more common with dupilumab treatment (5.0%) than with placebo (1.2%). The OCS maintenance population showed similar outcomes. CONCLUSION: Dupilumab significantly improved lung function and asthma control, numerically reduced asthma exacerbations, and was well tolerated in patients from China and India with persistent asthma and evidence of either type 2 inflammation or OCS maintenance. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03782532.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 CONSORT flowchart. OCS, oral corticosteroid; q2w, every 2 weeks. a 37 participants (dupilumab 200 mg q2w, n = 20; matched placebo, n = 17) were without type 2 inflammation or OCS maintenance at baseline.
非 KM Figure
FIGURE 2FIGURE 2 LS mean change from baseline in pre‐bronchodilator FEV 1 (L) up to week 24 in patients with persistent asthma and a type 2 inflammatory phenotype without OCS maintenance. FEV 1 , forced expiratory volume in 1 s; LS, least squares; OCS, oral corticosteroid; q2w, every 2 weeks; SE, standard error.
非 KM Figure
FIGURE 3FIGURE 3 LS mean change from baseline in ACQ ‐5 score up to week 24 in patients with persistent asthma and a type 2 inflammatory phenotype without OCS maintenance. ACQ ‐5, 5‐item Asthma Control Questionnaire; LS , least squares; OCS , oral corticosteroid; q2w, every 2 weeks; SE , standard error.
非 KM Figure
FIGURE 4FIGURE 4 Severe exacerbation rate until week 24 in patients with asthma and a type 2 inflammatory phenotype without OCS maintenance. OCS, oral corticosteroid; q2w, every 2 weeks. a Data shown are mean values. **nominal p < 0.01.
非 KM Figure